Biocon has entered into collaboration with CCM Pharmaceuticals, a subsidiary of Chemical Company of Malaysia, whereby the India’s premier biotechnology company has granted CCM an exclusive licence and distribution rights for its insulin products in Malaysia and Brunei. Both the companies are targeting an insulin market of around close to Rs 160 crore.
Besides, this collaboration has given the Bangalore-based biotechnology firm a second partner to market its insulin products. Earlier this year, US drug maker Pfizer had scrapped an arrangement to sell Biocon’s injectable insulin products.
Further, last month Biocon had inked a deal with Bristol-Myers Squibb giving it exclusive rights to develop and commercialize its oral insulin, on condition that the outcome of clinical trials are positive.
Biocon is India’s premier biotechnology company with a strategic focus on biopharmaceuticals and research services. Biocon produces anti-diabetic agents like Acarbose, Pioglitazone, Repaglinides and Rosiglitazone. In the biological segment it produces Insulin, Erythropoietin (EPO), Filgrastim (GCSF), Streptokinase and Monoclonal Antibodies.
